BioBehavioral Diagnostics Names New VP of Marketing.--Stephen Butts brings extensive experience in delivering market-leading products to ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or patients-- CAMBRIDGE, Mass. -- BioBehavioral Diagnostics Company (BioBDx), recently appointed Stephen E. Butts as vice president of marketing and sales. Mr. Butts Mr. Butts is a character in Garry Trudeau's comic strip Doonesbury. When Mike Doonesbury was asked to create an ad campaign aimed at teenage smokers, he suffered a morality crisis, and the hallucinatory Mr. Butts was the result. An eight-foot-tall (2. has over 14 years experience in marketing and sales for pharmaceutical firms, most recently as U.S. marketing director at Eli Lilly and Co, leading the effort to market Straterra[R] (atomoxetine HCL HCl hydrochloric acid. ). BioBDx is an innovator in diagnostic systems for Attention Deficit Hyperactivity Disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. (ADHD) and is currently commercializing its lead product -- the McLean Motion and Attention Test for ADHD (MMAT/ADHD[TM] System). "Stephen brings a wealth of proven experience in ADHD marketing and sales, which is vital as we prepare for the commercial launch of the MMAT/ADHD[TM] System," said Eric Gordon, founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BioBDx. "His deep understanding of the clinical challenges in diagnosing and treating ADHD, extensive skills in building a marketing and sales infrastructure, and incredible energy are all the ingredients we need to ensure we reach those patients and their clinicians who could benefit most from the MMAT/ADHD[TM] System." At Eli Lilly Mr. Butts was responsible for product launch planning and oversaw all marketing activities to support Strattera, an important non-stimulant medication option for both children and adults affected by ADHD. Under his guidance, sales reached $370 million in the first full year of the Strattera launch with second year sales exceeding $660 million. After guiding Strattera through launch, Mr. Butts was a regional sales director in Lilly's Primary Care Neuroscience Division responsible for Strattera, Cymbalta[R] (duloxetine HCL), and Symbyax [R] (olanzapine and fluoxetine fluoxetine /flu·ox·e·tine/ (floo-ok´se-ten) a selective serotonin reuptake inhibitor used as the hydrochloride salt in the treatment of depression, obsessive-compulsive disorder, bulimia nervosa, and premenstrual dysphoric disorder. HCL) BioBDx's lead product -- MMAT/ADHD[TM] System-- is a non-invasive, office-based FDA-cleared diagnostic system that provides evidence-based and objective measures of the core symptoms of ADHD: inattention in·at·ten·tion n. Lack of attention, notice, or regard. Noun 1. inattention - lack of attention basic cognitive process - cognitive processes involved in obtaining and storing knowledge (difficulty in staying focused and on task), hyperactivity hyperactivity, excessive physical activity of emotional or physiological origin, usually seen in young children; one of the components of attention deficit hyperactivity disorder. (inability to control movement and sit still while working), and impulsivity (inability to inhibit inappropriate responses). While the disorder is estimated to affect 8-12% of school aged children in the U.S., an accurate diagnosis is often difficult because it is based upon subjective interviews and assessments by clinicians, parents and teachers. The MMAT/ADHD[TM] System employs a novel set of proprietary technologies that provide objective and precise measures of the core symptoms of ADHD in a controlled and reproducible setting. "This is an incredible opportunity to address the need for objective behavioral measurements in the diagnosis, evaluation, and treatment of ADHD," said Mr. Butts. "BioBDx is advancing a completely new way of approaching the diagnosis and treatment of ADHD, which could allow clinicians to objectively diagnose ADHD and therefore improve treatment outcomes for patients. BioBDx is at the forefront of the diagnosis and management of behavioral disorders, such as ADHD, and may provide new hope for patients and parents." About the MMAT/ADHD[TM] System The MMAT/ADHD[TM] System objectively and quantitatively measures the three core symptoms of ADHD (inattention, hyperactivity and impulsivity), gauging a patient's ability to sit still and pay attention to a defined task, under controlled conditions that replicate a classroom or workplace environment. The data generated by the MMAT/ADHD[TM] System directly correlates to brain function as determined by functional magnetic resonance imaging functional magnetic resonance imaging n. Abbr. fMRI Magnetic resonance imaging that provides three-dimensional images of the brain based on changes in blood flow and that can be correlated with brain functions. (MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. ). About BioBDx BioBehavioral Diagnostics Company (BioBDx) is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. whose mission is to develop, manufacture, and market proprietary diagnostic systems for the quantitative assessment of behavioral disorders. The company's lead product, the McLean Motion and Attention Test for Attention Deficit Hyperactivity Disorder (MMAT/ADHD([TM])System), is designed to enable clinicians to accurately make office based diagnoses for ADHD, ensuring prompt and appropriate treatment. For more information on BioBDx, please visit http://www.biobdx.com/. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion